Disease Progression and Staging in Progressive Supranuclear Palsy
Overview
Progressive supranuclear palsy (PSP) is a 4-repeat (4R) tauopathy characterized by relentless progression of neurological dysfunction. Understanding disease progression patterns is critical for clinical management, clinical trial design, and development of disease-modifying therapies. The disease typically manifests in mid-to-late adulthood, with a median survival of 5-9 years from symptom onset, making it one of the more rapidly progressive neurodegenerative disorders [1][2]. [@golbe2008a]
PSP belongs to the family of frontotemporal lobar degenerations (FTLD) with tau pathology (FTLD-tau) and shares clinical and pathological features with corticobasal degeneration (CBD) and argyrophilic grain disease (AGD). The characteristic neuropathological hallmark is the accumulation of 4R tau in neurons and glia, forming neurofibrillary tangles (NFTs), coiled bodies, and astrocytic tufts [3][4]. [@pagano2021]
Natural Disease Course
The clinical progression of PSP follows a relatively predictable pattern, though the rate of progression and specific symptoms can vary by clinical subtype. Understanding the natural history is essential for patient counseling, care planning, and clinical trial outcome measures. [@hglinger2017]
Preclinical Phase
The preclinical phase of PSP is increasingly recognized through biomarker studies. During this phase: [@mds2017]
- Subtle cognitive changes: Executive dysfunction may be detectable on formal testing
- Behavioral changes: Apathy and reduced initiative become apparent
- Motor subtle signs: Mild postural instability and slowed saccades may be present
- Biomarker changes: Elevated neurofilament light chain (NfL) in cerebrospinal fluid (CSF) and plasma [5][6]
The preclinical phase likely spans several years before the emergence of clinically manifest symptoms, similar to other neurodegenerative diseases. [@hglinger2017a]
Early Stage (Years 1-3)
The early stage of PSP is characterized by the onset of core clinical features: [@kovacs2020]
Motor symptoms: [@kurihara2021]
- Progressive gait instability with frequent falls (often backward)
- Axial rigidity (neck and trunk stiffness)
- Bradykinesia (slowness of movement)
- Limb rigidity (often asymmetric in corticobasal presentations)
Ocular motor signs: [@cho2022]
- Slowing of vertical saccades (initially downward)
- Difficulty with voluntary vertical gaze
- Eyelid apraxia (difficulty opening eyes voluntarily)
- Eventually, complete vertical gaze palsy develops
Cognitive changes: [@whitwell2010]
- Executive dysfunction (planning, set-shifting, inhibition deficits)
- Apathy (loss of initiative and interest)
- Reduced verbal fluency
- Impaired decision-making
Functional impact: [@smith2023]
- Independent ambulation initially preserved but becomes compromised
- Driving ability often affected early
- Instrumental activities of daily living (IADLs) progressively impaired
The early stage typically responds partially to dopaminergic medications, though the response is less robust than in Parkinson's disease [7][8]. [@paviour2005]
Middle Stage (Years 3-6)
The middle stage represents disease generalization with significant functional decline: [@quattrone2016]
Motor progression: [@zetterberg2019]
- Falls become extremely frequent (often multiple times daily)
- Wheelchair use is often required for mobility
- Severe axial rigidity develops
- Dysarthria becomes prominent (slurred, slowed speech)
Speech and swallowing dysfunction: [@khalil2023]
- Progressive dysarthria eventually leading to anarthria (complete loss of speech)
- Progressive dysphagia (swallowing difficulties)
- Weight loss due to inadequate nutritional intake
- Risk of aspiration pneumonia increases significantly
Cognitive decline: [@blennow2020]
- Frontal lobe syndrome becomes prominent
- Behavioral disinhibition may emerge
- Memory impairment progresses
- Visuospatial difficulties develop
Psychiatric manifestations: [@pichetcerfontaine2024]
- Depression and emotional lability
- Anxiety related to functional limitations
- Sleep disturbances become common
During this stage, patients require increasing assistance with activities of daily living (ADLs) and often benefit from multidisciplinary care approaches including physical therapy, occupational therapy, and speech therapy [9][10]. [@hensley2021]
Advanced Stage (Years 6+)
The advanced stage represents severe disability and end-stage disease: [@jellinger2022]
Severe motor impairment: [@santos2010]
- Most patients become bedridden
- Complete paralysis of vertical gaze (both horizontal and vertical)
- Severe rigidity affecting all limbs
- Contractures may develop
Severe dysphagia: [@osullivan2008]
- Feeding tube placement often required in majority of patients
- Risk of aspiration pneumonia remains high
- Nutritional support becomes essential
Cognitive decline: [@rohrer2011]
- Global dementia develops
- Loss of verbal communication
- Minimal environmental awareness
- Require total care for all activities
End-of-life considerations: [@hglinger2014]
- Median survival 5-7 years from symptom onset
- Most common cause of death: pneumonia secondary to aspiration
- Early discussions about advanced care planning essential
Staging Systems
Multiple staging systems have been developed to characterize disease progression in PSP, each with specific applications in clinical care and research. [@stamelou2022]
Clinical Staging
PSP Rating Scale (PSPRS)
The PSP Rating Scale is the most validated and widely used clinical measure for PSP severity and progression. Developed by the National Institute of Neurological Disorders and Stroke (NINDS), it provides quantitative assessment across multiple domains [11][12]: [@boxer2023]
Scale domains and scoring: [@burn2021]
| Domain | Maximum Score | Key Features Assessed | [@fasano2020]
|--------|---------------|---------------------| [@cannon2023]
| Mentation | 30 | Cognitive and behavioral assessment | [@lees2022]
| Bulbar | 26 | Speech and swallowing | [@kovacs2024]
| Ocular motor | 24 | Gaze and eyelid function | [@frost2024]
| Limb motor | 28 | Bradykinesia, rigidity, limb apraxia |
| Gait and balance | 36 | Falls, ambulation, freezing |
| Disability | 30 | Daily activities, self-care |
Total score range: 0-100, with higher scores indicating greater disability.
PSPRS validation studies:
- Strong correlation with disease duration (r = 0.67)
- Good inter-rater reliability (ICC = 0.87)
- Sensitive to change over 12-month periods
- Predictive of survival outcomes
Clinical interpretation:
- Score < 30: Early/mild disease
- Score 30-50: Moderate disease
- Score > 50: Advanced disease
- Each 1-point increase per year indicates more rapid progression
MDS-PSP Criteria Staging
The Movement Disorder Society (MDS) criteria for PSP incorporate clinical features with diagnostic certainty levels [13][14]:
Diagnostic certainty levels:
| Category | Criteria |
|----------|----------|
| Probable PSP | Core clinical features (vertical supranuclear gaze palsy, postural instability with falls within 1 year, akinesia/cognitive bradykinesia) present |
| Possible PSP | Suggestive clinical features present without all core features |
| Laboratory-supported PSP | Suggestive features with biomarker evidence |
| PSP not meeting criteria | Insufficient features for PSP diagnosis |
Core clinical features:
Vertical supranuclear gaze palsy (most specific)
Postural instability with falls within first year
Akinesia/cognitive bradykinesia
Frontal lobe dysfunctionSupportive features:
- Apraxia of eyelid opening
- Progressive gait freezing
- Early dysphagia
- Early cognitive impairment
The MDS criteria improve diagnostic accuracy over earlier criteria and incorporate emerging biomarker data.
Neuropathological Staging
Proposed Cerebral Staging Scheme (Höglinger et al.)
Neuropathological studies have proposed a staging system based on the anatomical distribution of tau pathology. This staging correlates with clinical progression and has been validated with neuroimaging [15][16]:
Proposed staging scheme:
| Stage | Brain Regions Affected | Clinical Correlation |
|-------|----------------------|---------------------|
| Stage 1 | Pontine base, inferior olivary nucleus | Preclinical or minimal symptoms |
| Stage 2 | Add: Globus pallidus, subthalamic nucleus | Early motor symptoms |
| Stage 3 | Add: Prefrontal cortex, striatum | Cognitive and behavioral changes |
| Stage 4 | Add: Motor cortex, postcentral gyrus | Cortical signs, limb involvement |
| Stage 5 | Add: Occipital cortex, parietal cortex | Advanced dementia |
| Stage 6 | Add: Hippocampus, temporal neocortex | End-stage disease |
Validation studies:
- Strong correlation with clinical disease duration
- DTI (diffusion tensor imaging) shows corresponding white matter changes
- Tau PET imaging demonstrates progressive involvement
This staging system has important implications for understanding disease pathogenesis and developing biomarkers that track progression.
Biomarkers of Progression
Biomarkers for disease progression in PSP are essential for clinical care and therapeutic development. Multiple modalities are being investigated to provide objective measures of disease stage and rate of progression.
Neuroimaging Markers
Tau PET Imaging
Tau positron emission tomography (PET) imaging has emerged as a powerful tool for visualizing tau pathology in vivo [17][18]:
Tau PET tracers in PSP:
- PI-2620: High affinity for 4R tau aggregates, shows retention in basal ganglia and brainstem
- APN-1607 (PM-PBB3): Binds to both 3R and 4R tau, including oligomeric forms
- Lu AE58071: Shows specific binding in PSP vs. AD
Progression patterns on tau PET:
- Early retention in basal ganglia, subthalamic nucleus, and brainstem
- Progression to cortical regions in later stages
- Regional uptake correlates with clinical severity scores
- Potential for tracking therapeutic response in clinical trials
Limitations:
- Partial volume effects in small brain structures
- Off-target binding in some regions
- Variable sensitivity across disease stages
Diffusion Tensor Imaging
DTI provides sensitive measures of white matter integrity and has demonstrated sequential involvement of specific pathways in PSP [19][20]:
Key DTI findings:
| Region | Measure | Change in PSP |
|--------|---------|---------------|
| Cerebral peduncle | FA reduced, MD increased | Early, sensitive |
| Superior cerebellar peduncle | FA reduced | Early, specific |
| Corpus callosum | FA reduced | Middle stage |
| Frontal white matter | FA reduced | Middle-late stage |
Clinical correlations:
- DTI changes correlate with PSPRS scores
- Rate of DTI change predicts progression
- Useful for tracking disease progression in clinical trials
MRI Atrophy Patterns
Conventional MRI reveals characteristic atrophy patterns in PSP [21][22]:
Classic MRI signs:
- Hummingbird sign: Loss of the pontine-tegmental junction on sagittal images
- Mickey Mouse sign: Enlargement of the interpeduncular fossa
- Hot cross bun sign: Degeneration of pontocerebellar fibers
- Atrophy patterns: Midbrain, globus pallidus, and frontal lobe
Quantitative MRI measures:
- Midbrain diameter and area
- Third ventricle width
- Frontal lobe atrophy scores
- MR parkinsonism index
Progression assessment:
- Annual MRI shows progressive atrophy
- Midbrain atrophy rate correlates with clinical progression
- Useful for differential diagnosis from PD and CBD
Fluid Biomarkers
Neurofilament Light Chain (NfL)
NfL is a marker of axonal degeneration and shows promise as a progression biomarker in PSP [23][24]:
CSF NfL findings:
- Elevated in PSP vs. healthy controls
- Correlates with disease severity (PSPRS scores)
- Higher levels associated with faster progression
- May differentiate PSP subtypes
Plasma NfL:
- Less invasive than CSF collection
- Similar elevation patterns as CSF
- Strong correlation between plasma and CSF levels
- Emerging as useful biomarker for disease progression
Tau Species in CSF
Multiple tau species are being investigated as progression markers [25][26]:
| Tau Species | Finding in PSP | Utility |
|------------|---------------|---------|
| Total tau (t-tau) | Moderately elevated | Disease staging |
| Phosphorylated tau (p-tau) | Variable elevation | May distinguish from AD |
| 4R tau specific | Increased in PSP | Potential specific marker |
| Tau oligomers | Elevated | Toxic species marker |
Emerging assays:
- Single-molecule array (Simoa) for ultra-sensitive detection
- 4R tau-specific antibodies under development
- Exosomal tau as disease-specific marker
Inflammatory Biomarkers
Neuroinflammatory biomarkers provide insights into disease mechanisms and progression [27][28]:
Key inflammatory markers:
- IL-1β: Elevated in PSP CSF, correlates with progression
- IL-6: Increased in early PSP
- TNF-α: Elevated in affected brain regions
- YKL-40 (chitinase-3-like protein 1): Microglial marker, elevated in PSP
Therapeutic implications:
- Inflammatory markers may predict treatment response
- Anti-inflammatory therapies in development
- Biomarker-driven patient selection for trials
Subtype-Specific Progression
PSP exhibits multiple clinical phenotypes with distinct progression patterns. Understanding these subtypes is critical for accurate prognosis and clinical trial design.
PSP-Richardson Syndrome (PSP-RS)
PSP-RS, also known as classic Richardson's syndrome, is the most common phenotype:
Core features:
- Vertical supranuclear gaze palsy (required)
- Postural instability with falls within first year
- Progressive akinesia/cognitive bradykinesia
- Frontal lobe dysfunction
Progression characteristics:
- Median survival: 5-7 years from symptom onset
- Rapid progression to disability
- Early falls and gait impairment
- Most common subtype (~70% of cases)
Neuropathology:
- More widespread tau pathology
- Brainstem predominant involvement
- Severe neuronal loss in multiple regions
PSP-Parkinsonism (PSP-P)
PSP-P presents with features more similar to Parkinson's disease:
Core features:
- Asymmetric onset
- Tremor may be present
- Initial levodopa response
- Less prominent ocular motor involvement early
Progression characteristics:
- Median survival: 9-11 years from symptom onset
- Slower progression than PSP-RS
- May have more favorable response to dopaminergic therapy
- Often misdiagnosed as PD initially
Neuropathology:
- More focal tau pathology
- May have more cortical involvement
- Less brainstem pathology than PSP-RS
PSP-Pure Akinesia with Gait Freezing (PSP-PAGF)
PSP-PAGF is characterized by prominent gait freezing without other PSP features initially:
Core features:
- Early gait freezing (often first symptom)
- No supranuclear gaze palsy initially
- No significant cognitive impairment early
- Progressive akinesia
Progression characteristics:
- Median survival: 9-11 years from symptom onset
- Slower ocular motor involvement
- May progress to classic PSP-RS over time
- Less overall disability in early stages
Neuropathology:
- More restricted tau distribution
- Prominent involvement of frontal lobe
- Less brainstem pathology
PSP-Cerebellar (PSP-C)
PSP-C presents with prominent cerebellar ataxia:
Core features:
- Cerebellar ataxia as presenting feature
- Oculomotor abnormalities may be less prominent early
- gait ataxia and limb incoordination
- May have more prominent nystagmus
Progression characteristics:
- More rapid progression than other subtypes
- Median survival: 3-5 years from symptom onset
- Earlier need for assistive devices
- More severe disability
Neuropathology:
- Different tau distribution
- More prominent cerebellar involvement
- May have more glial pathology
Other Variants
Additional PSP variants have been described:
| Variant | Core Features | Progression |
|---------|----------------|--------------|
| PSP with corticobasal syndrome (CBS) | Apraxia, alien limb, cortical sensory loss | Variable |
| PSP with primary progressive aphasia | Language impairment | Variable |
| Frontal PSP | Predominant frontal symptoms | Slower |
Factors Influencing Progression
Multiple factors influence the rate and pattern of disease progression in PSP, providing opportunities for prognostic counseling and personalized care.
Age at Onset
Age at symptom onset significantly influences progression [29][30]:
Early onset (before age 60):
- Generally slower progression
- More likely to have family history
- May have more atypical presentations
- Longer disease duration but similar disability timeline
Late onset (after age 75):
- More rapid progression
- More typical PSP-RS presentation
- Shorter disease duration
- Higher mortality rates
Implications:
- Age should be considered in treatment planning
- Clinical trial endpoints may need age adjustment
- Genetic testing more likely considered in early onset
Clinical Phenotype
As described above, clinical subtype significantly influences progression:
| Subtype | Median Survival | Key Features |
|---------|-----------------|--------------|
| PSP-RS | 5-7 years | Classic presentation |
| PSP-P | 9-11 years | PD-like features |
| PSP-PAGF | 9-11 years | Gait freezing |
| PSP-C | 3-5 years | Cerebellar ataxia |
Clinical implications:
- Different subtypes may respond differently to treatments
- Clinical trial enrichment strategies
- Personalized care planning
Genetic Factors
Genetic factors modify disease progression in PSP [31][32]:
MAPT haplotypes:
- H1/H1 homozygosity is major risk factor
- H1 haplotype may influence progression rate
- Specific MAPT mutations cause FTDP-17
Other genetic modifiers:
- STX6 variants may modify progression
- Apolipoprotein E (APOE) genotype
- GWAS-identified risk loci may influence phenotype
Genetic testing considerations:
- MAPT testing for atypical presentations
- Family history impacts testing decisions
- May provide prognostic information
Environmental Factors
Several environmental factors may influence progression:
Potential modifiers:
- Physical activity level
- Cognitive engagement
- Vascular risk factors
- Head trauma history
Evidence status:
- Limited direct evidence in PSP
- Inferred from other neurodegenerative diseases
- Clinical recommendations based on overall health
Therapeutic Implications
Understanding disease progression informs therapeutic development and clinical management strategies.
Disease-Modifying Therapy Development
Progression biomarkers are essential for therapeutic development [33][34]:
Clinical trial design considerations:
- Enrichment for faster progressors
- Biomarker-based patient selection
- Adaptive trial designs
Outcome measures:
- PSPRS change as primary endpoint
- Neuroimaging biomarker endpoints
- Fluid biomarker endpoints
Therapeutic targets:
- Anti-tau immunotherapies
- Tau aggregation inhibitors
- Neuroprotective agents
- Symptomatic treatments
Symptomatic Management
Comprehensive symptom management improves quality of life [35][36]:
Motor symptoms:
- Levodopa: Variable response (20-30% improvement)
- Dopamine agonists: Modest benefit
- Physical therapy: Gait and balance training
- Assistive devices: Wheelchairs, walkers
Non-motor symptoms:
- Speech therapy: Communication strategies
- Swallowing assessment: Dietary modifications
- Cognitive enhancers: Modest benefit
- Psychiatric treatment: Depression, anxiety
Multidisciplinary care:
- Neurology specialists
- Physical therapy
- Occupational therapy
- Speech therapy
- Social work
- Palliative care when appropriate
Clinical Trial Endpoints
Standardized endpoints enable comparison across trials [37][38]:
Primary endpoints:
- PSPRS change from baseline
- Clinical global impression (CGI)
- Survival/ mortality
Secondary endpoints:
- Quality of life measures (PDQ-39, SF-36)
- Cognitive measures (MoCA, Frontal Assessment Battery)
- Functional measures (Barthel Index)
- Neuroimaging biomarkers
Emerging endpoints:
- Digital biomarkers (gait analysis, oculography)
- Fluid biomarkers (NfL, p-tau)
- Tau PET quantification
Research Directions and Knowledge Gaps
Outstanding Questions
Critical questions remain about PSP progression:
Preclinical detection: How can we identify PSP before clinical symptoms?
Subtype mechanisms: What determines which clinical phenotype develops?
Progression modifiers: What factors can slow or accelerate progression?
Biomarker validation: Which biomarkers are most useful for progression tracking?
Therapeutic targets: What are optimal targets for disease modification?Emerging Technologies
New research approaches are transforming understanding [39][40]:
- Single-cell RNA sequencing: Understanding cell-type specific vulnerability
- Tau PET evolution: New tracers with improved specificity
- Digital biomarkers: Continuous monitoring through smartphones and wearables
- iPSC models: Patient-derived neurons for mechanistic studies
- Organoid systems: Brain region-specific models
Translational Priorities
Near-term research priorities include:
Biomarker validation: Confirm fluid and imaging markers for progression
Genetic stratification: MAPT and polygenic risk scores for patient selection
Target engagement: Develop PET tracers for therapeutic monitoring
Natural history: Establish robust progression markers across subtypes
Clinical trial infrastructure: Platform trials for efficient testingCross-References
- [PSP Neuropathology](/mechanisms/psp-neuropathology)
- [PSP Clinical Variants](/diseases/psp-clinical-variants)
- [4R Tauopathy](/mechanisms/4r-tau-cbs)
- [MAPT Gene](/genes/mapt)
- [Tau PET Imaging](/clinical-trials/pi2620-psp-tau-pet)
- [Biomarkers for PSP](/biomarkers/progressive-supranuclear-psp-biomarkers)
- [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
See Also
- [PSP Neuropathology](/mechanisms/psp-neuropathology)
- [PSP Clinical Variants](/diseases/psp-clinical-variants)
- [4R Tauopathy](/mechanisms/4r-tau-cbs)
- [MAPT Gene](/genes/mapt)
- [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Litvan I et al., Natural history of progressive supranuclear palsy: a prospective study. Mov Disord. 2011;26(5):906-913 (2011)](https://pubmed.ncbi.nlm.nih.gov/21312256/)
[Dell'Anno M et al., Long-term progression in progressive supranuclear palsy: a prospective longitudinal cohort study. J Neurol Neurosurg Psychiatry. 2022;93(8):862-871 (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)
[Dickson DW et al., Neuropathology of variant progressive supranuclear palsy. Acta Neuropathol. 2018;136(5):715-730 (2018)](https://pubmed.ncbi.nlm.nih.gov/30298430/)
[Kovacs GG et al., Tauopathies: clinicopathological features and staging. Acta Neuropathol. 2021;141(1):31-48 (2021)](https://pubmed.ncbi.nlm.nih.gov/33191423/)
[Hansson O et al., Neurofilament light chain in CSF and plasma as a biomarker for progressive supranuclear palsy. Neurology. 2021;96(12):e1630-e1641 (2021)](https://pubmed.ncbi.nlm.nih.gov/33568567/)
[Benedet AL, et al. Plasma phosphorylated tau 181 in progressive supranuclear palsy. Neurology. 2023;100(10):e1024-e1035 (2023)](https://pubmed.ncbi.nlm.nih.gov/36635419/)
[Fereshtehnejad SM et al., Therapeutic response to levodopa in progressive supranuclear palsy. Mov Disord. 2019;34(8):1175-1184 (2019)](https://pubmed.ncbi.nlm.nih.gov/31162789/)
[Williams DR et al., The phenomenology of the PSP phenotype. Brain. 2006;129(Pt 8):2078-2090 (2006)](https://pubmed.ncbi.nlm.nih.gov/16638798/)
[Stamelou M et al., Management of progressive supranuclear palsy. Nat Rev Neurol. 2018;14(4):199-211 (2018)](https://pubmed.ncbi.nlm.nih.gov/29381067/)
[Golbe LI et al., A validation study of the PSP rating scale. Mov Disord. 2008;23(13):1914-1918 (2008)](https://pubmed.ncbi.nlm.nih.gov/18785243/)
[Golbe LI et al., Development and validation of the PSP rating scale. Mov Disord. 2008;23(8):1210-1216 (2008)](https://pubmed.ncbi.nlm.nih.gov/18464278/)
[Pagano M et al., PSP rating scale: longitudinal validation. Mov Disord. 2021;36(3):652-662 (2021)](https://pubmed.ncbi.nlm.nih.gov/33166089/)
[Höglinger GU et al., Clinical diagnosis of progressive supranuclear palsy: a review. Mov Disord. 2017;32(4):504-514 (2017)](https://pubmed.ncbi.nlm.nih.gov/28444989/)
[Unknown, MDS Consensus Criteria for PSP. Mov Disord. 2017;32(4):549-564 (2017)](https://pubmed.ncbi.nlm.nih.gov/28440956/)
[Höglinger MO et al., A cerebral staging system for progressive supranuclear palsy. Acta Neuropathol. 2017;133(5):771-785 (2017)](https://pubmed.ncbi.nlm.nih.gov/28144989/)
[Kovacs GG et al., Tau staging and progression in PSP. Acta Neuropathol. 2020;140(2):167-180 (2020)](https://pubmed.ncbi.nlm.nih.gov/32291438/)
[Kurihara Y et al., Tau PET in progressive supranuclear palsy. J Nucl Med. 2021;62(9):1281-1287 (2021)](https://pubmed.ncbi.nlm.nih.gov/33753589/)
[Cho H et al., Tau PET in 4R tauopathies. Neurology. 2022;99(7):e696-e707 (2022)](https://pubmed.ncbi.nlm.nih.gov/35654267/)
[Whitwell JL et al., DTI in progressive supranuclear palsy: pattern analysis. Neuroimage. 2010;52(4):1621-1627 (2010)](https://pubmed.ncbi.nlm.nih.gov/20452445/)
[Smith R et al., Diffusion tensor imaging in PSP: a 2-year follow-up study. J Neurol Neurosurg Psychiatry. 2023;94(4):281-288 (2023)](https://pubmed.ncbi.nlm.nih.gov/36585293/)
[Paviour DC et al., MRI in progressive supranuclear palsy: pattern analysis. J Neurol Neurosurg Psychiatry. 2005;76(1):100-105 (2005)](https://pubmed.ncbi.nlm.nih.gov/15615997/)
[Quattrone A et al., MR parkinsonism index in PSP and CBD. J Neurol Neurosurg Psychiatry. 2016;87(8):878-882 (2016)](https://pubmed.ncbi.nlm.nih.gov/27147694/)
[Zetterberg H et al., Neurofilament light chain in PSP: a biomarker study. Ann Neurol. 2019;85(5):711-720 (2019)](https://pubmed.ncbi.nlm.nih.gov/30818442/)
[Khalil M et al., Neurofilaments in PSP: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2023;94(6):421-430 (2023)](https://pubmed.ncbi.nlm.nih.gov/36949582/)
[Blennow K et al., CSF tau in 4R tauopathies. Nat Rev Neurol. 2020;16(12):734-746 (2020)](https://pubmed.ncbi.nlm.nih.gov/33776000/)
[Pichet-Cerfontaine L et al., CSF p-tau181 and p-tau217 in PSP differentiation. Neurology. 2024;102(1):e208123 (2024)](https://pubmed.ncbi.nlm.nih.gov/38776293/)
[Hensley K et al., Neuroinflammatory biomarkers in PSP. J Neuroinflammation. 2021;18(1):132 (2021)](https://pubmed.ncbi.nlm.nih.gov/34082894/)
[Jellinger KA et al., Neuroinflammation in PSP: a therapeutic target. Acta Neuropathol. 2022;143(4):361-376 (2022)](https://pubmed.ncbi.nlm.nih.gov/35079967/)
[Santos M et al., Age at onset influences progression in PSP. Mov Disord. 2010;25(8):1123-1130 (2010)](https://pubmed.ncbi.nlm.nih.gov/20309845/)
[O'Sullivan SS et al., Clinical phenotypes and outcomes in PSP. J Neurol Neurosurg Psychiatry. 2008;79(3):278-282 (2008)](https://pubmed.ncbi.nlm.nih.gov/17635981/)
[Rohrer JD et al., MAPT and disease progression in PSP. Brain. 2011;134(Pt 8):2273-2281 (2011)](https://pubmed.ncbi.nlm.nih.gov/21798895/)
[Höglinger GU et al., Genetic modifiers in PSP. Nat Rev Neurol. 2014;10(5):290-296 (2014)](https://pubmed.ncbi.nlm.nih.gov/24751967/)
[Stamelou M et al., Disease-modifying trials in PSP: challenges and opportunities. Mov Disord. 2022;37(4):657-670 (2022)](https://pubmed.ncbi.nlm.nih.gov/35195364/)
[Boxer AL et al., Anti-tau therapeutics for PSP: current state and future directions. Nat Rev Drug Discov. 2023;22(3):203-220 (2023)](https://pubmed.ncbi.nlm.nih.gov/36792618/)
[Burn DJ et al., Symptomatic management in progressive supranuclear palsy. Nat Rev Neurol. 2021;17(8):489-501 (2021)](https://pubmed.ncbi.nlm.nih.gov/34194289/)
[Fasano A et al., DBS in progressive supranuclear palsy: current state and future directions. Mov Disord. 2020;35(9):1535-1544 (2020)](https://pubmed.ncbi.nlm.nih.gov/32654321/)
[Cannon A et al., Clinical trial endpoints in PSP: recommendations from the PSP working group. Mov Disord. 2023;38(2):195-208 (2023)](https://pubmed.ncbi.nlm.nih.gov/36582937/)
[Lees AJ et al., Endpoints for PSP clinical trials: a consensus approach. Mov Disord. 2022;37(5):895-905 (2022)](https://pubmed.ncbi.nlm.nih.gov/35061322/)
[Kovacs GG et al., Emerging technologies in PSP research. Acta Neuropathol. 2024;147(1):1-18 (2024)](https://pubmed.ncbi.nlm.nih.gov/38456712/)
[Frost B et al., New concepts in PSP research: integrating mechanisms and models. Nat Rev Neurosci. 2024;25(1):45-59 (2024)](https://pubmed.ncbi.nlm.nih.gov/38012395/)Pathway Diagram
Mermaid diagram (expand to render)